Evidence map›Paper›PMID 27507538›Full record

ArticleMolecular oncology2016

MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.

Hirosha Geekiyanage, Evanthia Galanis

Open access · greenAbstract read
In one paragraph

Article in Molecular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. miR-31-5p-Oncology letters · 2022
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. MicroRNA-31 Regulates Expression ofInternational journal of molecular sciences · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hirosha GeekiyanageDepartment of Molecular Medicine, Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA. Electronic address: geekiyanage.donahirosha@mayo.edu.
Evanthia GalanisDepartment of Molecular Medicine, Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA. Electronic address: galanis.evanthia@mayo.edu.
Mayo Clinic in Arizona · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
Optimizing Measles Virotherapy in the Treatment of Ovarian CancerR01CA136547 · NCI · MAYO CLINIC ROCHESTER · PI GALANIS, EVANTHIA, PENG, KAH-WHYE · 2009 to 2012
$2.0M
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomasR01CA154348 · NCI · MAYO CLINIC ROCHESTER · PI GALANIS, EVANTHIA · 2011 to 2014
$1.3M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA108961NCI NIH HHS P50 CA116201NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA136547NCI NIH HHS R01 CA154348
6 · The paper itself

Abstract

Oncolytic measles virus strains are currently being evaluated in several clinical trials, as a promising novel oncolytic platform. Poliovirus receptor-related 4 (PVRL4) was recently identified as a potent measles virus (MV) receptor; however, its regulation is not yet understood. Increased levels of PVRL4 protein were observed in cell membrane, cytoplasm and nuclei of glioblastoma, breast and ovarian tumor clinical samples with no significant change in PVRL4 mRNA levels in glioblastoma and breast cancer compared with their corresponding control samples, suggesting that PVRL4 is likely post-transcriptionally regulated. Therefore, we sought to investigate the potential role of miRNAs in PVRL4 regulation and thus MV infectivity. We demonstrated that miR-31 and miR-128 can bind to the 3'UTR of PVRL4 and decrease PVRL4 levels while anti-miR-31/128 increase PVRL4 levels suggesting that PVRL4 is miRNA targeted. Furthermore, miR-31/128 expression levels were down-regulated in glioblastoma and breast tumor samples and showed significant negative correlations with PVRL4 levels. Infection with an MV strain that exclusively utilizes PVRL4 as its receptor showed that over-expression of miR-31/128 decreases MV infectivity while inhibition of the respective miRNAs via anti-miRs increase MV infectivity and reduce tumor size in mouse xenograft models of glioblastoma, breast and ovarian cancer. Additionally, miR-128 levels showed significant correlations with MV infection and in vivo anti-tumor effect, while MV infection increased miR-31 expression and thereby contributed to the observed decrease in PVRL4 levels. This study suggests that PVRL4 is post-transcriptionally regulated by miR-128 and miR-31 and harbors possible miRNA targets that could modulate MV infectivity and in turn enhance MV based oncolytic therapeutic strategies.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBase SequenceCell Adhesion MoleculesCell Line, TumorHumansMeasles virusMice, NudeMicroRNAsNectinsNeoplasmsRNA, MessengerTumor BurdenCell Adhesion MoleculesMicroRNAsMIRN128 microRNA, humanMIRN31 microRNA, humanNECTIN4 protein, humanNectinsRNA, MessengerBreast cancerGlioblastomaMeasles virusmiRNAOvarian cancerPVRL4

Identifiers

PMID27507538
PMCPMC5100694
OpenAlexW2476001891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.